In February 2013, a novel avian influenza H7N9 virus emerged in China, and has caused significant mortality and morbidity in humans. Since the human population is expected to 
Since early 2013, the emergence of a novel avian influenza A H7N9 virus in China has caused 445 confirmed human infections in 17 provinces of China, with at least 113 deaths by July 8th, 2013, resulting in a case fatality rate at over 25% [1] . As serologic assays have showed that no, or very low levels of pre-existing immunity was detected against the A/H7N9 virus in any of the age groups, including high-risk population, this may highlight that a worldwide outbreak is almost certain if H7N9 viruses acquire the ability to efficient and sustained human-to-human trans--mission [2] [3] [4] [5] . To meet the challenge of H7N9 influenza pandemic that may occur, [6] .
One the other hand, various H7N9 vaccines are being developed by vaccine research institutes and manufacturing companies, and several of them are currently being evaluated in clinical trials (Table 1 ) [7] . could not meet the licensure criteria [10] .
These results suggest that the MF59-adjuvanted vaccine [11, 12] .
However, it should be noted that in the MF59 adjuvanted vaccine trials, if a more sensitive method microneutrali--zation (MN) assay was used for neutralizing antibodies detection, a [13] [14] [15] .
Therefore, more consideration should be taken for the research and development of effective H7N9 vaccines than that for seasonal flu, and other prepandemic and (Hualan Bio) and Sinovac Biotech Co., Ltd (Sinovac). As for now, the BTBP has got its clinical trial approvals from state FDA and the applications of other three enterprises are now also being accepted [16] . nonhuman primates, their efficacy in human subjects remains to be evaluated [17] [18] [19] .
Therefore, the clinical trials may be carried out in the future when situation of epidemic prevention and control is needed. It is worth mentioning that the standard antiserum against H7N9 hemagglutinin was once successfully developed by National Institute for Food and Drug Control before the WHO potency testing reagents were available, and these reagents were effectively applied to the quantitative detection of antigen in H7N9 vaccines by vaccine enterprises [20] .
Although there is no apparent need for immediate mass production of H7N9 vaccine at present, vaccine preparation should be considered as the most important intervention if a pandemic occurs. As the low immunogenicity of H7N9 vaccines appears to have been indicated, novel strategies that could improve protection GMT was defined as the geometric mean titer of HI antibody titer, seroconversion rate (SCR) was defined as the percent of participants achieving a four or more fold increase in HI antibody titer or an increase from a level below the limit of detection (<1:10) to at least 1:40, seroprotection rate (SPR) was defined as the percent of participants achieving an HI antibody titer ≥1:40 b Serological studies were performed 3 and 2 weeks after the second dose for recombinant virus like particle vaccine and MDCK cell-derived sub-virion vaccine respectively -The data could not be obtained from figs in the reference ability against H7N9 are required. First of all, since the low immunogenicity of 
